Staff Profile

Roles and Responsibilities

• Development and validation of assays for the quantification of anti-cancer drugs
• Generation of assay validation plans and reports
• Analysis of patient samples collected during clinical trials
• Planning and communication of experimental strategies
• Analysis and interpretation of experimental data

Qualifications

• BSc Biology (Hons), Newcastle University
• Ph.D. (Molecular Biosciences), Newcastle University

I am a Research Associate at the Newcastle University Centre for Cancer, based in the Paul O’Gorman Building. Our research involves investigating the pharmacokinetics of chemotherapeutic agents that are used to treat cancer in both adults and children.

• Articles

  • Bell HL, Blair HJ, Jepson Gosling SJ, Galler M, Astley D, Moorman AV, Heidenreich O, Veal GJ, van Delft FW, Lunec J, Irving JAE. Combination p53 activation and BCL-x_L/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia 2024, 38, 1223-1235.
  • Barnett S, Nyein AC, Galler M, Jamieson D, Davies M, Connor P, Veal GJ. Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report. Cancer Chemotherapy and Pharmacology 2023, 92, 325–328.
  • Cao M, Day AM, Galler M, Latimer HR, Byrne DP, Foy TW, Dwyer E, Bennett E, Palmer J, Morgan BA, Eyers PA, Veal EA. A peroxiredoxin-P38 MAPK scaffold increases MAPK activity by MAP3K-independent mechanisms. Molecular Cell 2023, 83(17), 3140-3154.e7.
  • Barter MJ, Butcher A, Wang H, Tsompani D, Galler M, Rumsby EL, Culley KL, Clark IM, Young DA. HDAC6 regulates NF-κB signalling to control chondrocyte IL-1-induced MMP and inflammatory gene expression. Scientific Reports 2022, 12(1), 6640.
  • Byrne DP, Shrestha S, Galler M, Cao M, Daly L, Campbell AE, Eyers CE, Veal EA, Kannan N, Eyers PA. Aurora A regulation by reversible cysteine oxidation reveals evolutionary-conserved redox-control of Ser/Thr protein kinase activity. Science Signaling 2020, 13(639).
  • Almeida GS, Bawn CM, Galler M, Wilson I, Thomas HD, Kyle S, Curtin NJ, Newell DR, Maxwell RJ. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR in Biomedicine 2017, 30(9), e3736.
  • Harnor SJ, Rennison T, Galler M, Cano C, Griffin RJ, Newell DR, Golding BT. Synthesis of 3 '-deoxy-3'-fluorothymidine (FLT) 5 '-O-glucuronide: a reference standard for imaging studies with [¹⁸F]FLT. MedChemComm 2014, 5(7), 984-988.
  • Bui C, Barter MJ, Scott JL, Xu Y, Galler M, Reynard LN, Rowan AD, Young DA. cAMP response element-binding (CREB) recruitment following a specific CpG demethylation leads to the elevated expression of the matrix metalloproteinase 13 in human articular chondrocytes and osteoarthritis. FASEB Journal 2012, 26(7), 3000-3011.